LOTREL
LOE ApproachingNDAORALCAPSULE
Approved
Mar 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
6/8 — Strong
LOTREL by Novartis is angiotensin-converting enzyme (ace) in human subjects and in animals. Approved for hypertension in patients not adequately controlled on monotherapy with either agent () 1, hypertension in patients not adequately controlled on monotherapy with either agent. First approved in 1995.
Drug data last refreshed 19h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOTREL is a fixed-dose combination of amlodipine besylate (a calcium channel blocker) and benazepril hydrochloride (an ACE inhibitor) indicated for hypertension management. This oral capsule combines two complementary mechanisms to reduce blood pressure in patients who require dual antihypertensive therapy. It has been a cornerstone antihypertensive since its 1995 approval.
$0.003BPart D
LOE ApproachingDeclining
Declining Part D spending and LOE approaching signal a mature franchise with shrinking commercial teams and reduced field headcount.
Mechanism of Action
angiotensin-converting enzyme (ACE) in human subjects and in animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results…
Worked on LOTREL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.